Cargando…
Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer
Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.(1) Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascula...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Journal of the ASEAN Federation of Endocrine Societies
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784230/ https://www.ncbi.nlm.nih.gov/pubmed/33442102 http://dx.doi.org/10.15605/jafes.032.02.12 |
_version_ | 1783632266934616064 |
---|---|
author | Dharan, Shalini Sree Kamaruddin, Nor Azmi |
author_facet | Dharan, Shalini Sree Kamaruddin, Nor Azmi |
author_sort | Dharan, Shalini Sree |
collection | PubMed |
description | Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.(1) Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascular, respiratory and metabolic co-morbidities, it has also been proven to cause an increased incidence of cancer. The main treatment of acromegaly is surgical excision of the functioning pituitary adenoma. Multiple comorbidities, including obstructive sleep apnea (OSA), left ventricular hypertrophy (LVH) and soft tissue swelling, make surgery complicated, if not impossible. Medical therapy to reduce comorbidities may be indicated in certain situations. Somatostatin receptor ligands (SRL) are able to reduce, and possibly normalize, IGF-1 levels.(2) Reduction of insulin-like growth factor-1 (IGF-1), the main mediator of GH, is able to resolve headache, sweating, fatigue and soft tissue swelling, and also reduce ventricular hypertrophy. This case report illustrates the successful use of the SRL octreotide LAR in treating acromegaly. It also confirms the observation from several case series that thyroid cancer is the most common malignancy in acromegaly. |
format | Online Article Text |
id | pubmed-7784230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Journal of the ASEAN Federation of Endocrine Societies |
record_format | MEDLINE/PubMed |
spelling | pubmed-77842302021-01-12 Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer Dharan, Shalini Sree Kamaruddin, Nor Azmi J ASEAN Fed Endocr Soc Case Report Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.(1) Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascular, respiratory and metabolic co-morbidities, it has also been proven to cause an increased incidence of cancer. The main treatment of acromegaly is surgical excision of the functioning pituitary adenoma. Multiple comorbidities, including obstructive sleep apnea (OSA), left ventricular hypertrophy (LVH) and soft tissue swelling, make surgery complicated, if not impossible. Medical therapy to reduce comorbidities may be indicated in certain situations. Somatostatin receptor ligands (SRL) are able to reduce, and possibly normalize, IGF-1 levels.(2) Reduction of insulin-like growth factor-1 (IGF-1), the main mediator of GH, is able to resolve headache, sweating, fatigue and soft tissue swelling, and also reduce ventricular hypertrophy. This case report illustrates the successful use of the SRL octreotide LAR in treating acromegaly. It also confirms the observation from several case series that thyroid cancer is the most common malignancy in acromegaly. Journal of the ASEAN Federation of Endocrine Societies 2017-09-30 2017 /pmc/articles/PMC7784230/ /pubmed/33442102 http://dx.doi.org/10.15605/jafes.032.02.12 Text en © 2017 Journal of the ASEAN Federation of Endocrine Societies https://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. |
spellingShingle | Case Report Dharan, Shalini Sree Kamaruddin, Nor Azmi Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer |
title | Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer |
title_full | Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer |
title_fullStr | Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer |
title_full_unstemmed | Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer |
title_short | Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer |
title_sort | successful primary medical therapy with somatostatin receptor ligand in acromegaly with thyroid cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784230/ https://www.ncbi.nlm.nih.gov/pubmed/33442102 http://dx.doi.org/10.15605/jafes.032.02.12 |
work_keys_str_mv | AT dharanshalinisree successfulprimarymedicaltherapywithsomatostatinreceptorligandinacromegalywiththyroidcancer AT kamaruddinnorazmi successfulprimarymedicaltherapywithsomatostatinreceptorligandinacromegalywiththyroidcancer |